SETDB1 and Its Impact on Liver Cancer Prognosis
Author Information
Author(s): Yin Chang-Qing, Song Chun-Qing, Gallay Philippe, Weiskirchen Ralf
Primary Institution: Westlake University
Hypothesis
Elevated levels of SETDB1 correlate with poorer overall survival in hepatocellular carcinoma (HCC) patients.
Conclusion
Higher SETDB1 expression is linked to worse prognosis in HCC patients and reduced immune cell infiltration.
Supporting Evidence
- SETDB1 expression was significantly higher in HCC compared to normal tissues.
- HCC patients with high SETDB1 expression had poorer overall survival.
- SETDB1 negatively correlated with immune cell infiltration.
- SETDB1 may serve as a predictive marker for immunotherapy response.
Takeaway
SETDB1 is a protein that, when found in high amounts in liver cancer, can mean the patient might not do as well. It also seems to keep immune cells from helping fight the cancer.
Methodology
The study analyzed SETDB1 expression in HCC using data from TCGA and GEO, performed survival analysis, and conducted in vivo and ex vivo experiments.
Potential Biases
Potential biases may arise from the reliance on existing databases and the specific experimental models used.
Limitations
The study primarily relied on in silico analysis and used a specific mouse model, limiting broader applicability.
Participant Demographics
The study included 374 HCC samples, with a notable correlation to gender.
Statistical Information
P-Value
p = 0.029
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website